In our current work, which combines data from TCGA and GEO public databases as well as tissue microarrays, we validated the clinical implication of BGN expression in colon cancer samples and utilized multiple bioinformatics approaches to investigate the underlying immunosuppressive mechanisms of BGN in the TME as well as its potential role in predicting immune checkpoint blocker (ICB) immunotherapy responses in colon cancer patients. The gene discussed is BGN; the disease is malignant colon neoplasm.